IRCT20230903059343N1尚未招募2 期
Comparing the effect of Empagliflozin, Pioglitazone and their combination, on sonographic and biochemical features of non-alcoholic fatty liver disease in diabetic patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 65 years（—）
- 性别
- All
入选标准
- •All patients with type 2 diabetes phenotype and fatty liver disease
排除标准
- •History of alcohol ingestion
- •Heart failure, NYHA class III or IV
- •Chronic kidney disease with GFR<45 ml/min
- •Other chronic liver diseases including viral or autoimmune hepatitis
- •Current use of Empagliflozine or Pioglitazone
- •Use of known causative drugs for fatty liver including NSAIDs, Tamoxifen, Amiodarone and Valproate
- •Use of antioxidant agents during the past 3 months, including Vitamin C, Zinc or Selenium-containing supplements.
- •HbA1c less than 7 or more than 9 percent
- •Type 1 diabetes or diabetes due to a specific secondary cause
- •Pregnancy or Lactation
- •Active cancer during the last two years
- •Cardiovascular events during the last 3 months
- •History of hypothyroidism
- •Wilson's disease
- •BMI>40 kg/m2
- •History of biliary obstruction
- •Glucocorticoid use for 2 weeks during the last 2 months
研究者
相似试验
已完成
3 期
Comparing the effect of Empagliflozin with Pioglitazone on nonalcoholic fatty liverIRCT20220928056051N1Oroumia University of Medical Sciences60
已完成
2 期
The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patientsIRCT20190122042450N3Iran University of Medical Sciences105
尚未招募
2 期
The effect of Empagliflozin on nonalcoholic fatty liver disease in non-diabetic patientson alcoholic fatty liver disease.Nonalcoholic steatohepatitis [NASH]K75.81IRCT20190122042450N1Iran University of Medical Sciences100
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
招募中
2 期
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesK75.81CardiomyopathyIRCT20190122042450N5Iran University of Medical Sciences70